RFL
Rafael Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Rafael Holdings, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Rafael Holdings, Inc.
1.13
No other changes.
No other changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Rafael Holdings, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Rafael Holdings, Inc..
Annual filing, covered
10-K parsed · Oct 29 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Oct 29 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $4.5M | 34.63% | +8.42% |
| Geodeindex-like | $1.4M | 10.90% | −2.83% |
| BlackRockindex-like | $1.3M | 9.89% | +6.69% |
| Dimensional | $914,749 | 7.07% | 0.00% |
| Vanguard Fiduciary Trustindex-like | $677,389 | 5.24% | +0.76% |
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $4.5M | 34.63% | +8.42% |
| Geodeindex-like | $1.4M | 10.90% | −2.83% |
| BlackRockindex-like | $1.3M | 9.89% | +6.69% |
| Dimensional | $914,749 | 7.07% | 0.00% |
| Vanguard Fiduciary Trustindex-like | $677,389 | 5.24% | +0.76% |
Expected move
No implied move.